Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-14 (canceled).

Claim 15(currently amended): A method for preventing or treating physiological changes due to hypergastrinemia in a mammal comprising co-administering to said mammal with hypergastrinemia an effective amount of an immunogenic composition comprising a G17 peptide fragment of SEQ ID NO: 1, said composition reducing ~~that reduces~~ the circulating hormone, gastrin, and an agent selected from the group consisting of a histamine H_2 receptor blocker and a proton pump inhibitor.

Claim 16 (original): The method according to claim 15, wherein said immunogenic composition comprises a peptide conjugated to an immunogenic carrier and a pharmaceutically acceptable carrier.

Claim 17 (currently amended). The method according to claim 16, wherein said ~~immunogenic composition is selected from the group consisting of a~~ G17 peptide fragment ~~SEQ ID NO: 1~~ is linked by an amino acid spacer to an immunogenic carrier~~; a G34 peptide fragment SEQ ID NO: 2 linked by an amino acid spacer to an immunogenic carrier; a combination of said G17 and G34 fragments linked by an amino acid spacer to an immunogenic carrier~~.

Claim 18 (original): The method according to claim 17, wherein said carrier is selected from the group consisting of diphtheria toxoid, tetanus toxoid, and keylimpet hemocyanin.

Claims 19-24 (canceled)

Claim 25 (currently amended): The method according to claim ~~24~~ 15, wherein said blocker is selected from the group consisting of ranitidine, cimetidine, fomatidine, and nizatidine.

Claim 26 (currently amended): The method according to claim ~~24~~ 15, wherein said inhibitor is selected from the group consisting of omeprazole, lansoprazole and pantoprazole.

Claim 27 (currently amended): The method according to claim ~~24~~ 15, wherein said mammal is administered said immunogenic composition before said agent.

Claim 28 (canceled)

Claim 29 (original): The method according to claim 15, wherein said hypergastrinemia is associated with a condition selected from the group consisting of pernicious anemia, a gastric tumor, a gastric cancer, and a course of therapy with a substance that results in increased gastrin levels.

Claims 30-43 (canceled)

Claim 44 (new): The method according to claim 15, wherein said composition comprises anti-gastrin antibodies that bind to gastrin.

Claim 45 (new): The method according to claim 44, wherein said antibodies are purified or humanized.

Claim 46 (new): The method according to claim 44, wherein said antibodies bind to heptadecagastrin G17.

Claim 47 (new): The method according to claim 15, wherein said hypergastrinemia is associated with a course of therapy with a substance that results in increased gastrin levels.

Claim 48 (new): The method according to claim 47, wherein said hypergastrinemia is induced by administration of said substance alone.

Claim 49 (new): The method according to claim 15, wherein said physiopathological changes are the development of a cancer selected from the group consisting of colon cancer, stomach cancer, pancreatic cancer, esophageal cancer and liver cancer, wherein said co-administration occurs prior to the development of malignancy.